Oral administration of butylated hydroxytoluene induces neuroprotection in a streptozotocin-induced rat Alzheimer’s disease model via inhibition of neuronal ferroptosis
Our data indicate that oral BHT treatment attenuated the development of AD-related symptoms in an in vivo rat model, most probably via inhibiting neuronal ferroptosis. These findings suggest that BHT might constitute a promising candidate as anti-AD drug. However, more work is needed to explore the potential applicability of BHT in other models of neurodegeneration and in additional ferroptosis-related disorders.
Authors
- Parisa Faraji
- Hartmut Kühn (ORCID: https://orcid.org/0000-0001-8142-3192)
- Elham Zahedi (ORCID: https://orcid.org/0009-0000-2465-1164)
- Elham Parandavar
- Mehran Habibi-Rezaei (ORCID: https://orcid.org/0000-0002-4819-8613)
- Astrid Borchert (ORCID: https://orcid.org/0000-0003-3551-5592)
- Shahin Ahmadian (ORCID: https://orcid.org/0000-0002-3436-465X)
Institutions
- University of Tehran (IR)
- Humboldt-Universität zu Berlin (DE)
- Institute of Biochemistry (HU)
- Tehran University of Medical Sciences (IR)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1186/s10020-024-00980-y
- Citations
- 2
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Charité – Universitätsmedizin Berlin